In particular, in the European Union (EU), it was initially authorized as monotherapy or as add-on combination therapy with other glucose-lowering agents for type 2 diabetes mellitus (T2DM), and lately, in 2019, for overweight patients with type 1 diabetes mellitus (T1DM) not sufficiently controlled with high doses of insulin. The gene discussed is INS; the disease is diabetes mellitus.